BPC-157 vs Cortexin

BPC-157 and Cortexin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.

Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.

Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs, containing a mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals. Unlike single-sequence peptides, it is a multi-component extract. Registered as a pharmaceutical in Russia and CIS countries since 1999 for neurological conditions including ischemic stroke, TBI, and cognitive impairment. Not approved by FDA, EMA, or other Western regulatory agencies. Research demonstrates multi-target neuroprotective activity including caspase-8 inhibition, antioxidant defense, and BDNF modulation.

Key claims: Neuroprotection in ischemic stroke; Inhibits brain caspase-8 (anti-apoptotic); Antioxidant effects in cerebrovascular insufficiency.

These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Cortexin targets Neuroprotection, Stroke Recovery, Cognitive Support.

BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.

Cortexin: Substantial clinical safety record through pharmaceutical use in Russia/CIS since 1999 Most common adverse effect: injection site reactions (pain, redness, swelling) from IM administration Rare allergic/hypersensitivity reactions reported (consistent with animal-derived protein composition)